Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Michael A. Carducci

Oncology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Offers Telehealth
Distinguished in WT1-Related Wilms Tumor Syndromes
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Carducci is an Oncologist in Baltimore, Maryland. Dr. Carducci is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Orchiectomy.

His clinical research consists of co-authoring 274 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Sibley Memorial Hospital
The Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287
Other Locations
JOHNS HOPKINS UNIVERSITY
8600 Old Georgetown Rd, Bethesda, MD 20814
JOHNS HOPKINS UNIVERSITY
5255 Loughboro Rd Nw, Washington, DC 20016

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Phase I/II Study of High Dose Interleukin 2, Aldesleukin, in Combination With the Histone Deacetylase Inhibitor Entinostat in Patients With Metastatic Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Radiation, Other, Biological
Study Drugs: Aldesleukin, Entinostat
Study Phase: Phase 1/Phase 2
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2025
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Drug
Study Drugs: Etrumadenant, Zimberelimab, AB680, Enzalutamide, Docetaxel
Study Phase: Phase 1/Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
A Phase 2 Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC)
Enrollment Status: Terminated
Publish Date: June 21, 2024
Intervention Type: Drug
Study Phase: Phase 2
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy
Enrollment Status: Unknown
Publish Date: May 31, 2023
Intervention Type: Drug, Radiation
Study Drug: Enzalutamide
Study Phase: Phase 2
PACCT: Partnering Around Cancer Clinical Trials
PACCT: Partnering Around Cancer Clinical Trials
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Behavioral
Study Phase: Not Applicable
Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin
Enrollment Status: Terminated
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction
Enrollment Status: Withdrawn
Publish Date: February 07, 2020
Intervention Type: Drug, Other
Study Phase: Phase 1
View 10 Less Clinical Trials

274 Total Publications

Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 07, 2025
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Heather D. Mannuel
Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Heather D. Mannuel
Oncology | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Heather Mannuel is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mannuel is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, and Prostate Cancer. Dr. Mannuel is currently accepting new patients.

Arif I. Hussain
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arif I. Hussain
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Arif I. Hussain
Oncology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (1.9 miles away)
410-328-1230
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Arif Hussain is an Oncologist in Baltimore, Maryland. Dr. Hussain is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Familial Prostate Cancer, and Prostate Cancer. Dr. Hussain is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (45.7 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Carducci's expertise for a condition
ConditionClose
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile